In March, the US Food and Drug Administration (FDA) granted Cereno Scientific’s preclinical candidate CS-1 (valproic acid) Orphan Drug Designation for pulmonary arterial hypertension.
GlobalData supposes that CS-1 could fill a gap in the market due to its innovative mechanism of action, particularly epigenetic modulation of cardiovascular disease by histone deacetylase inhibition.
Related Companies

Curtis Health Caps
Contract Development and Manufacturing Services for Pharmaceutical Projects